ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

  • P-ISSN1225-0163
  • E-ISSN2288-8985
  • SCOPUS, ESCI, KCI

논문 상세

Home > 논문 상세
  • P-ISSN 1225-0163
  • E-ISSN 2288-8985

논문 상세

    LC-QTOF-MS를 이용한 발기부전치료제 유사물질의 fragmentation pathway 분석

    Identification and evaluation of fragmentation pathways of PDE-5 inhibitor analogues using LC-QTOF-MS

    분석과학 / Analytical Science and Technology, (P)1225-0163; (E)2288-8985
    2015, v.28 no.4, pp.278-287
    https://doi.org/10.5806/AST.2015.28.4.278
    도정아 (식품의약품안전처)
    노은영 (식품의약품안전처, 식품의약품안전평가원)
    윤순병 (식품의약품안전처 식품의약품안전평가원 독성평가연구부 첨단분석팀)
    박형준 (식품의약품안전처)
    조수열 (식품의약품안전처)
    박성관 (식품의약품안전청)
    윤창용 (식품의약품안전처)
    • 다운로드 수
    • 조회수

    Abstract

    Phosphodiesterase type 5 inhibitors (PDE-5 inhibitors) are used in the treatment of erectile dysfunction. In recent years, a number of reports have been conducted on dietary supplements contaminated with PDE-5 analogues. In this study, 58 analogues of PDE-5 inhibitors were sorted into five groups: tadalafil, sildenafil, hongdenafil, vardenafil, and other analogues. These analogues were then evaluated using a liquid chromatographyquadrupole- time of flight mass spectrometry (LC-QTOF-MS) electrospray ionization mass method. Each compound has a unique fragmentation ion, which can be easily analyzed qualitatively. The fragmentation pathways of the analogues were elucidated based on the QTOF-MS and MS/MS data. Common ions were confirmed for each group by analyzing the structural characteristics and fragmentation pathways. Specifically, common ions were observed at m/z 169.08 and 135.04 (tadalafil analogues), m/z 311.15 and 283.12 (sildenafil analogues and hongdenafil analogues), and m/z 312.16 and 151.09 (vardenafil analogues). The advantage of this method is that the structure of unknown components can be determined by interpreting the product ions. Hence, the developed method can be used for the identification of unknown compounds. Fragmentation pathways may also aid in the detection and identification of PDE-5 inhibitor analogues.

    keywords
    PDE-5, LC-QTOF-MS, fragmentation pathway, identification, unknown compounds


    참고문헌

    1

    1. B. J. Venhuis, G. Zomer, M. Hamzink, H. D. Meiring, Y. Aubin and D. de Kaste, J. Pharm. Biomed. Anal., 54(4), 735-741 (2011).

    2

    2. L. Blok-Tip, B. Zomer, F. Bakker, K. D. Hartog, M. Hamzink, J. Ten Hove, M. Vredenbregt, D. de Kaste, Food Addit. Contam., 21(8), 737-748 (2004).

    3

    4. Q. Liang, J. Qu, G. Luo and Y. Wang, J. Pharm. Biomed. Anal., 40(2), 305-311 (2006).

    4

    5. S. R. Gratz, C. L. Flurer and K. A. Wolnik, J. Pharm. Biomed. Anal., 36(3), 525-533 (2004).

    5

    6. M. H. Shin, M. K. Hong, W. S. Kim, Y. J. Lee and Y. C. Jeoung, Food Addit. Contam., 20(9), 793-798 (2003).

    6

    7. R. Yuan and Y. Lin, Pharmacol. Ther., 86(2), 191-198 (2000).

    7

    8. FDA approves Stendra for erectile dysfunction, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302140.htm/, Assessed 13 Jan 2001.

    8

    9. O. Shaeer. The Global Online Sexuality Survey (GOSS): The United States of America in 2011 Chapter II: phosphodiesterase inhibitors utilization among English speakers. J. Sex. Med., 10(2), 532-540 (2012).

    9

    10. A. W. Shindel. Update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. J. Sex. Med., 6, 2352-2364 (2009).

    10

    11. C. G. Stief, S. Uckert, A. J. Becker, M. C. Truss and U. Jonas, J. Urol., 159(4), 1390-1393 (1998).

    11

    12. B. J. Venhuis and D. Kaste, J. Pharm. Biomed. Anal., 69, 196-208 (2012).

    12

    13. M. Y. Low, Y. Zeng, L. Li, X. W. Ge, R. Lee and B. C. Bloodworth, H. L. Koh, Drug Saf., 32(12), 1141-1146 (2009).

    13

    13. Illicit erectile dysfunction products in the Netherlands http://www.rivm.nl/Documenten_en_publicaties/Wetenschappelijk/Rapporten/2011/september/Illicit_erectile_dysfunction_products_in_the_Netherlands_A_decade_of_trends_and_a_2007_2010_product_update/,Assessed 8 Sept 2011.

    14

    14. M. Sugita and M. Miyakawa, Health Preventive Med., 15(4), 244-251 (2010).

    15

    15. S. Singh, B. Prasad, A. A. Savaliya, R. P. Shah and V. M. Gohil, A. Kaur, Trends Anal. Chem., 28(1), 13-28 (2009).

    16

    16. J. B. Guo, Y. Xu, Z. B. Huang, Q. H. He, S. W. Liu, Anal. Chim., 658(2), 197-203 (2010).

    17

    17. S. M. Khalil, Microchim., 158, 233-238 (2007).

    18

    18. C. M. Gryniewicz, J. C. Reepmeyer, J. F. Kauffman and L. F. Buhse, J. Pharm. Biomed. Anal., 49(3), 601-606 (2009).

    19

    19. D. J. Mans, R. J. Callahan, J. D. Dunn and C. M. Gryniewicz-Ruzicka, J. Pharm. Biomed. Anal., 75(5), 153-157 (2013).

    20

    20. D. Z. Mao, X. X. Weng and Y. J. Yang, J. Raman Spectrosc., 43(12), 1985-1990 (2012).

    21

    21. C. L. Cheng, G. J. Kang and C. H. Chou, J. Chromatogr., 1154(1-2), 222-229 (2007).

    22

    22. M. Park and S. Ahn, J. Forensic Sci., 57(6), 1637-1640 (2012).

    23

    23. P. Y. Sacre, E. Deconinck, P. Chiap, J. Crommen, F. Mansion, E. Rozet, P. Courselle and J. O. De Beer, J. Chromatogr., 1218(37), 6439-6447 (2011).

    24

    24. C. N. Man, N. M. Noor and R. Lajis, J. Chromatogr., 1218(39), 7055-7060 (2011).

    25

    25. P. Nikolaou, I. Papoutsis, S. Athanaselis, G. Alevisopoulos, A. Khraiwesh, C. Pistos and C. Spiliopoulou, J. Pharm. Biomed. Anal., 56(3), 577-581 (2011).

    26

    26. R. Patterson, P. Mabe, E. N. Mitchell and W. Cory, Forensic Sci. Int., 222(1-3), 83-88 (2012).

    27

    27. C. S. Ng, T. Y. Law, Y. K. Cheung, P. C. Ng and K. K. Choi, Anal. Methods., 2, 890-896 (2010).

    28

    28. Y. Ren, C. S. Wu and J. L. Zhang, J. Sep. Sci., 35(21), 2847-2857 (2012).

    29

    29. M. E. Hadwiger, M. L. Trehy, W. Ye, T. Moore, J. Allgire and B. Westenberger, J. Chromatogr. A., 1217(48), 7547-7555 (2010).

    30

    30. Y. Cai, T. G. Cai, Y. Shi, X. L. Cheng, L. Y. Ma, S. C. Ma, R. C. Lin and W. Feng, J. Liq. Chromatogr. Rel. Technol., 33, 1287-1306 (2010).

    31

    31. A. Lanzarotta, J. B. Crowe, M. Witkowski and B. M. Gamble, J. Pharm. Biomed. Anal., 67-68, 22-27 (2012).

    32

    32. F. W. McLafferty. Interpretation of Mass Spectra, third edition. University Science Books, p 51-215, Mill Valley, California, 1980.

    33

    33. J. H. Lee, H. J. Kim, E. Noh, J. Y. Kim, S. H. Cho, J.-A Do, C.-Y. Yoon, S. Cho and W. S. Kim, J. Pharm. Biomed. Anal., 103, 80-84 (2015).

    상단으로 이동

    분석과학